| Title |
Antibody–Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments
|
|---|---|
| Published in |
Targeted Oncology, November 2017
|
| DOI | 10.1007/s11523-017-0535-0 |
| Pubmed ID | |
| Authors |
Aiko Nagayama, Leif W. Ellisen, Bruce Chabner, Aditya Bardia |
| Abstract |
Antibody-drug conjugates (ADCs) are complex immunoconjugates designed to selectively deliver toxic small molecules preferentially to cancer cells. These immunoconjugates consist of a monoclonal antibody - directed to a tumor antigen - and a cytotoxic agent that is conjugated to the antibody via a molecular linker. Following the binding to a specific antigen on the surface of cancer cells, the conjugate is internalized and releases its cytotoxic payload to kill the malignant cell. ADCs that have gained regulatory approval from the US Food and Drug Administration (FDA) include brentuximab vedotin for CD30-positive Hodgkin's lymphoma and trastuzumab emtansine for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Several other agents are in advanced stages of clinical development, including sacituzumab govitecan for breast cancer, mirvetuximab soravtansine for ovarian cancer, rovalpituzumab tesirine for lung cancer, depatuxizumab mafodotin for glioblastoma, and oportuzumab monatox for bladder cancer. This review provides an overview of the recent clinical experience with the approved, most advanced, and other promising candidates of ADCs for solid tumors, including a description of biology and chemistry of ADCs, drug resistance and biomarkers, and the future perspective on combination strategies with these new immunoconjugates. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 130 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 130 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 20 | 15% |
| Researcher | 19 | 15% |
| Student > Ph. D. Student | 17 | 13% |
| Student > Postgraduate | 11 | 8% |
| Other | 8 | 6% |
| Other | 15 | 12% |
| Unknown | 40 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 16% |
| Biochemistry, Genetics and Molecular Biology | 19 | 15% |
| Chemistry | 11 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 8% |
| Agricultural and Biological Sciences | 4 | 3% |
| Other | 18 | 14% |
| Unknown | 47 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 24. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 January 2024.
All research outputs
#1,558,780
of 25,231,854 outputs
Outputs from Targeted Oncology
#8
of 610 outputs
Outputs of similar age
#31,084
of 338,609 outputs
Outputs of similar age from Targeted Oncology
#2
of 16 outputs
Altmetric has tracked 25,231,854 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 610 research outputs from this source. They receive a mean Attention Score of 3.5. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 338,609 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.